{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:24:28Z","timestamp":1759332268354},"reference-count":124,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["patient-research.elsevier.com","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.ctrv.2013.11.003","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T21:52:36Z","timestamp":1385502756000},"page":"495-506","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review"],"prefix":"10.1016","volume":"40","author":[{"given":"Rossana","family":"Berardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariagrazia","family":"De Lisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Pagliaretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azzurra","family":"Onofri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Morgese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Savini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zelmira","family":"Ballatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Caramanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Mazzanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Cascinu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2013.11.003_b0005","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies","author":"Engels","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jso.10231","article-title":"Clinical spectrum of primary mediastinal tumors: a comparison of adult and pediatric populations at a single Japanese institution","author":"Takeda","year":"2003","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0015","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2013.11.003_b0020","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2004.10.113","article-title":"Tumor recurrence and survival in patient treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis","volume":"22","author":"Strobel","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0025","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.athoracsur.2008.12.095","article-title":"Thymomas: review of current clinical practice","volume":"87","author":"Tomaszek","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2013.11.003_b0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2003.09.022","article-title":"Multimodal management of stages III\u2013IVa malignant thymoma","volume":"44","author":"Bretti","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7326\/0003-4819-129-2-199807150-00006","article-title":"A multidisciplinary approach to therapy for unresectablemalignant thymoma","volume":"129","author":"Shin","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2013.11.003_b0040","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.athoracsur.2008.11.022","article-title":"Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis","volume":"87","author":"Korst","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2013.11.003_b0045","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0003-4975(97)00629-2","article-title":"Multimodality treatment of thymoma: a prospective study","volume":"64","author":"Venuta","year":"1997","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2013.11.003_b0050","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"A phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000097944","article-title":"Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients","volume":"70","author":"Maruyama","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2013.11.003_b0060","series-title":"WHO International histological classification of tumors","first-page":"5","article-title":"Histological typing of tumors of the thymus","author":"Rosai","year":"1999"},{"key":"10.1016\/j.ctrv.2013.11.003_b0065","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.athoracsur.2003.10.001","article-title":"Thymic tumors","volume":"77","author":"Detterbeck","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2013.11.003_b0070","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/cncr.23492","article-title":"Evidence based pathology and the pathologic evaluation of thymomas","volume":"112","author":"Marchevsky","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0075","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1309\/CAV8-RNU5-TKNA-CKNC","article-title":"Thymoma classification: current status and future trends","volume":"125","author":"Suster","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0080","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0085","doi-asserted-by":"crossref","first-page":"s1710","DOI":"10.1097\/JTO.0b013e31821e8cff","article-title":"The Masaoka\u2013Koga stage classification for thymic malignancies: clarification and definition of terms","volume":"6","author":"Detterbeck","year":"2011","journal-title":"JTO"},{"issue":"1","key":"10.1016\/j.ctrv.2013.11.003_b0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3816\/CLC.2004.n.018","article-title":"Thymoma and thymic carcinoma: therapeutic approaches","volume":"6","author":"Kurup","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0095","doi-asserted-by":"crossref","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","article-title":"Chemotherapy definitions and policies for thymic malignancies","volume":"6","author":"Girard","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2013.11.003_b0100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000421-199308000-00014","article-title":"EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma","volume":"16","author":"Bonomi","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0105","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","article-title":"Treatment of invasive thymoma with single-agent ifosfamide","volume":"17","author":"Highley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0110","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002371-199510000-00005","article-title":"A phase II trial of subcutaneously administered recombinant human interleukin-2 in patients with relapsed\/refractory thymoma","volume":"18","author":"Gordon","year":"1995","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2013.11.003_b0115","first-page":"7079","article-title":"A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma","volume":"24","author":"Loehrer","year":"2006","journal-title":"ASCO Annu Meet Proc"},{"key":"10.1016\/j.ctrv.2013.11.003_b0120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11864-012-0211-7","article-title":"Treatment updates in advanced thymoma and thymic carcinoma","volume":"13","author":"Gubens","year":"2012","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2013.11.003_b0125","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jjco\/hyf059","article-title":"A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy","volume":"32","author":"Umemura","year":"2002","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2013.11.003_b0130","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/JTO.0b013e3181db3dee","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: a French experience","volume":"5","author":"Grassin","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2013.11.003_b0135","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/era.12.29","article-title":"Chemotherapy and targeted agents for thymic malignancies","volume":"12","author":"Girard","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2013.11.003_b0140","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combinated etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0145","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1183\/09059180.00007312","article-title":"Thymic epithelial tumours: from basic principles to individualised treatment strategies","volume":"22","author":"Girad","year":"2013","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ctrv.2013.11.003_b0150","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/JTO.0b013e31802bafc8","article-title":"Multimodality treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone","volume":"2","author":"Yokoi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma: a 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2013.11.003_b0165","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0022-5223(19)34092-9","article-title":"Chemotherapy and operation for invasive thymoma","volume":"106","author":"Rea","year":"1993","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"10.1016\/j.ctrv.2013.11.003_b0170","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bjc.6690773","article-title":"Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience","volume":"81","author":"Berruti","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0175","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00000421-200206000-00012","article-title":"Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy)","volume":"25","author":"Koizumi","year":"2002","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2013.11.003_b0180","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO;2-H","article-title":"Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma","volume":"68","author":"Macchiarini","year":"1991","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2013.11.003_b0185","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0003-4975(03)01020-8","article-title":"Long-term outcome after multimodality treatment for stage III thymic tumors","volume":"76","author":"Venuta","year":"2003","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"10.1016\/j.ctrv.2013.11.003_b0190","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.athoracsur.2004.12.047","article-title":"Advanced stage thymomas and thymic carcinomas: results of multimodality treatments","volume":"79","author":"Lucchi","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2013.11.003_b0195","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: a phase II study of the EORTC Lung Cancer Cooperative Group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0200","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1245\/s10434-010-1134-9","article-title":"New predictors of response to neoadjuvant chemotherapy and survival for invasive thymoma: a retrospective analysis","volume":"17","author":"Mineo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0205","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/1097-0142(19890415)63:8<1493::AID-CNCR2820630807>3.0.CO;2-C","article-title":"Chemotherapy of invasive thymoma: a retrospective study of 22 cases","volume":"63","author":"Goldel","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0210","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s101470200030","article-title":"Efficacy of induction chemoradiotherapy in thymic cancer: report of a successful case and review of the literature","volume":"7","author":"Morio","year":"2002","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0215","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/BF02913512","article-title":"Thymic carcinoma successfully resected with superior vena cava after chemoradiotherapy","volume":"49","author":"Shintani","year":"2001","journal-title":"Jpn J Thorac Cardiovasc Surg"},{"issue":"2","key":"10.1016\/j.ctrv.2013.11.003_b0220","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2009.03.031","article-title":"Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma","volume":"67","author":"Igawa","year":"2010","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2013.11.003_b0225","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jjco\/hyr089","article-title":"Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer","volume":"41","author":"Furugen","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0230","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0235","first-page":"31","author":"Takeda","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0240","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.11.003_b0245","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.lungcan.2011.05.013","article-title":"Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity","volume":"74","author":"Okuma","year":"2011","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2013.11.003_b0250","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1097-0142(19820801)50:3<419::AID-CNCR2820500306>3.0.CO;2-A","article-title":"Metastatic thymoma with myasthenia gravis: complete remission with combination chemotherapy","volume":"50","author":"Butler","year":"1982","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2013.11.003_b0255","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/1097-0142(19880501)61:9<1736::AID-CNCR2820610903>3.0.CO;2-T","article-title":"Combination chemotherapy with cyclophosphamide, adriamycin, and vincristine in malignant thymoma and myasthenia gravis","volume":"61","author":"Kosmidis","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0260","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","article-title":"Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)","volume":"21","author":"Palmieri","year":"2010","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2013.11.003_b0265","first-page":"208","article-title":"Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results","volume":"25","author":"Oshita","year":"1995","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2013.11.003_b0270","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.11606","article-title":"Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma","volume":"98","author":"Yoh","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0275","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.bjc.6605347","article-title":"A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)","volume":"101","author":"Kunitoh","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0280","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjc.6605731","article-title":"on behalf of JCOG Lung Cancer Study Group. A phase II trial of dose-dense chemotherapy, followed by surgical resection and\/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)","volume":"103","author":"Kunitoh","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0285","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/jcem.85.4.6547","article-title":"Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro","volume":"85","author":"Ferone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2013.11.003_b0290","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/cncr.10374","article-title":"Somatostatin analogs and prednisone in advanced refractory thymic tumors","volume":"94","author":"Palmieri","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2013.11.003_b0295","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group phase II trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0300","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2169\/internalmedicine.48.1922","article-title":"Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone","volume":"48","author":"Ito","year":"2009","journal-title":"Inter Med"},{"issue":"3","key":"10.1016\/j.ctrv.2013.11.003_b0305","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00432-001-0319-9","article-title":"Epidermal growth factor receptor expression in invasive thymoma","volume":"128","author":"Henley","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0310","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/cncr.20811","article-title":"Protein expression and gene amplification of epidermal growth factor receptor in thymomas","volume":"103","author":"Ionescu","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0315","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0320","doi-asserted-by":"crossref","first-page":"381s","DOI":"10.1200\/jco.2005.23.16_suppl.7068","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10 Suppl. 4","key":"10.1016\/j.ctrv.2013.11.003_b0325","doi-asserted-by":"crossref","DOI":"10.1097\/JTO.0b013e3181f20d9a","article-title":"The multidisciplinary approach to thymoma combining molecular and clinical approaches","volume":"5","author":"Chau","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0330","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.lungcan.2012.05.108","article-title":"HER family receptor and ligand status in thymic carcinoma","volume":"77","author":"Weissferdt","year":"2012","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2013.11.003_b0335","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0340","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front Biosci"},{"issue":"4","key":"10.1016\/j.ctrv.2013.11.003_b0345","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0092-8674(93)90499-G","article-title":"The p21 Cdk interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases","volume":"75","author":"Harper","year":"1993","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.ctrv.2013.11.003_b0350","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.11.003_b0355","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/cncr.21433","article-title":"Long-term disease-free survival of patients with radically resected thymomas: relevance of cell-cycle protein expression","volume":"104","author":"Mineo","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0360","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/annonc\/mdn388","article-title":"Response of malignant thymoma to erlotinib","volume":"19","author":"Christodoulou","year":"2008","journal-title":"Ann Oncol"},{"issue":"10 Suppl. 4","key":"10.1016\/j.ctrv.2013.11.003_b0365","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1097\/JTO.0b013e3181f209b9","article-title":"Thymic tumors: relevant molecular data in the clinic","volume":"5","author":"Girard","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0370","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00432-004-0545-z","article-title":"Tyrosine kinase receptor expression in thymomas","volume":"130","author":"Henley","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2013.11.003_b0375","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.22681","article-title":"L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition","volume":"121","author":"Antonescu","year":"2007","journal-title":"Int J Cancer"},{"issue":"25","key":"10.1016\/j.ctrv.2013.11.003_b0380","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overespression of mutated KIT and the response to imatinib","volume":"350","author":"Str\u00f6bel","year":"2004","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.ctrv.2013.11.003_b0385","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2013.11.003_b0390","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2010.09.011","article-title":"Promising efficacy of sorafenib in a relapsed thymic carcinoma with c-KIT exon 11 delection mutation","volume":"71","author":"Di\u015fel","year":"2011","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2013.11.003_b0395","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-011-1690-0","article-title":"Imatinib mesylate in thymic epithelial malignancies","volume":"69","author":"Palmieri","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0400","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methylphenyl)- 2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole- 5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2013.11.003_b0405","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1200\/JCO.2006.08.8963","article-title":"Dasatinib induces a response in malignant thymoma","volume":"24","author":"Chuah","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0410","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10585-004-2153-3","article-title":"Arg and DAP3 expression was correlated with human thymoma stage","volume":"21","author":"Sasaki","year":"2004","journal-title":"Clin Exp Metastasis"},{"issue":"7","key":"10.1016\/j.ctrv.2013.11.003_b0415","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2009-0009","article-title":"The role of Src in solid tumors","volume":"14","author":"Wheeler","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2013.11.003_b0420","unstructured":"Wakelee HA, Burns M, Gubens M, Barbeau S, Loehrer PJ. A phase II study of saracatinib (AZD0530), a SRC inhibitor, administered orally daily to patients (pts) with advanced thymic malignancies (ATM). Abstract submitted for the international thymic malignancy interest group (ITMIG) Conference, May 2010, New York."},{"key":"10.1016\/j.ctrv.2013.11.003_b0425","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1677\/joe.0.1520339","article-title":"Role of the IGF-I receptor in mutagenesis and tumor promotion","author":"Blakesley","year":"1997","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0430","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrc2536","article-title":"Insulin and insulin-like growth factor signalling in neoplasia","author":"Pollak","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0435","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1002\/cncr.25367","article-title":"Insulinlike growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas","volume":"116","author":"Zucali","year":"2010","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2013.11.003_b0440","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e3181e392a8","article-title":"Insulin-like growth factor-1 receptor expression in thymic malignancies","volume":"5","author":"Girard","year":"2010","journal-title":"Thorac Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0445","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","article-title":"Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors","volume":"13","author":"Haluska","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2013.11.003_b0450","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1517\/13543780903055049","article-title":"Cixutumumab","volume":"18","author":"McKian","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ctrv.2013.11.003_b0455","doi-asserted-by":"crossref","first-page":"e17525","DOI":"10.1200\/jco.2010.28.15_suppl.e17525","article-title":"Phase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC)","volume":"28","author":"Rajan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0460","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-10-1689","article-title":"Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors","volume":"17","author":"Breinig","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.11.003_b0465","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","article-title":"Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus","volume":"190","author":"Cimpean","year":"2008","journal-title":"Ann Anat"},{"key":"10.1016\/j.ctrv.2013.11.003_b0470","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s005950170021","article-title":"Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms","volume":"31","author":"Sasaki","year":"2001","journal-title":"Surg Today"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2013.11.003_b0475","doi-asserted-by":"crossref","first-page":"19087","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0480","doi-asserted-by":"crossref","first-page":"177s","DOI":"10.1200\/jco.2008.26.15_suppl.3599","article-title":"A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: Preliminary results","volume":"26","author":"Isambert","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0485","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/02841860802495362","article-title":"Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma","volume":"48","author":"Azad","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0490","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0495","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"issue":"10 Suppl. 4","key":"10.1016\/j.ctrv.2013.11.003_b0500","first-page":"5","article-title":"Thymoma and thymic carcinoma molecular pathology and targeted therapy","author":"Str\u00f6bel","year":"2010","journal-title":"J Thor Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0505","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11523-012-0235-8","article-title":"Long lasting efficacy of sorafenib in a heavily pre-treated patient with thymic carcinoma","volume":"7","author":"Neuhaus","year":"2012","journal-title":"Target Onccol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0510","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/annonc\/mdq313","article-title":"Phase I trial of SU14813 in patients with advanced solid malignancies","volume":"22","author":"Fiedler","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0515","first-page":"S1574","article-title":"HDAC inhibitor-based therapies: Can we interpret the code?","volume":"12","author":"New","year":"2012","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0520","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2013.11.003_b0525","article-title":"Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies","volume":"27","author":"Giaccone","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0530","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.3530","article-title":"A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors","volume":"27","author":"Brunetto","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0535","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-08-2196","article-title":"Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas","volume":"15","author":"Stewart","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.11.003_b0540","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.bjc.6601956","article-title":"Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells","volume":"91","author":"Shen","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2013.11.003_b0545","first-page":"2248","article-title":"Expression and activation of the nerve growth factor receptor Trk A in serous ovarian carcinoma","volume":"9","author":"Davidson","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.11.003_b0550","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejcts.2005.06.034","article-title":"Expression of neurotrophin receptors in surgically resected thymic epithelial tumors","volume":"28","author":"Kim","year":"2005","journal-title":"Eur J Cardiothorac Surg"},{"issue":"6","key":"10.1016\/j.ctrv.2013.11.003_b0555","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s10637-011-9774-6","article-title":"Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies","volume":"30","author":"Weiss","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2013.11.003_b0560","doi-asserted-by":"crossref","first-page":"S1698","DOI":"10.1097\/JTO.0b013e31821e7b12","article-title":"A review of prognostic factors in thymic malignancies","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b0855","doi-asserted-by":"crossref","unstructured":"Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, Connolly G, Debb G, Ramnath N. Am J Clin Oncol 27, 2004, 68-72.","DOI":"10.1097\/01.coc.0000046301.83671.09"},{"key":"10.1016\/j.ctrv.2013.11.003_b9005","first-page":"3093","article-title":"Chemotherapy of invasive thymoma","volume":"15","author":"Fornasiero","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b9010","first-page":"3093","article-title":"Chemotherapy of invasive thymoma","volume":"15","author":"Loehrer Sr","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b9015","doi-asserted-by":"crossref","first-page":"736","DOI":"10.7326\/0003-4819-99-5-736_1","article-title":"Chemotherapy for malignant thymoma","volume":"99","author":"Chahinian","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2013.11.003_b9020","doi-asserted-by":"crossref","unstructured":"Salter JT, Levis D, Yannoutsos C, Loehrer PJ, Risley L, Chiorean EG. Imatinib for the treatment of thymic carcinoma. J.Clin Oncol 26, 2008 (Suppl. Abstr. 8116).","DOI":"10.1200\/jco.2008.26.15_suppl.8116"},{"key":"10.1016\/j.ctrv.2013.11.003_b9025","unstructured":"Loehrer PJ. Pilot study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma (NCT00314873)."},{"key":"10.1016\/j.ctrv.2013.11.003_b9030","unstructured":"Wakelee HA, Burns M, Gubens M, Barbeau S, Loehrer PJ. A Phase II Study of Saracatinib (AZD0530), a SRC Inhibitor, Administered Orally Daily to Patients (pts) with Advanced Thymic Malignancies (ATM). Abstract submitted for the International Thymic Malignancy Interest Group (ITMIG) Conference; New York; 2010."},{"key":"10.1016\/j.ctrv.2013.11.003_b9035","unstructured":"Giaccone G. Multicenter Phase II Study of IMC-A12 in Patients with Thymoma and Thymic Carcinoma who have been previously treated with chemotherapy (NCT00965250)."},{"key":"10.1016\/j.ctrv.2013.11.003_b9040","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.11.003_b9045","unstructured":"Berman A. Sunitinib for advanced Thymus Cancer following earlier treatment (NCT01621568)."},{"key":"10.1016\/j.ctrv.2013.11.003_b9050","unstructured":"Scaburri A, Weiss G, Besse B, Novello S, Giaccone G, Mazi\u00e8res J, et al. Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma (NCT01011439)."},{"key":"10.1016\/j.ctrv.2013.11.003_b9055","unstructured":"Giaccone G. Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy (NCT01301391)."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213002314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213002314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T18:19:29Z","timestamp":1647541169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737213002314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0305737213002314"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.11.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}